As of June 30, 2024, the Company had cash and cash equivalents of approximately $6.4 million. In June 2024, the Company closed a public offering with aggregate gross proceeds of $4.0 million. Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
- GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
- GRI Bio Regains Compliance with Nasdaq
- GRI Bio regains compliance with Nasdaq